300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Recruiting
Life Science
Food and Beverage
Publishing
Web3
Mobile Apps
Medical
Wine and Spirits
Theatre
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Franchise
Financial Services
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Enterprise
Biotech
Transportation
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Singapore
Brazil
Oman
LATAM
Poland
Puerto Rico
Cameroon
Guernsey
China
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Grenada
Hungary
Lithuania
Israel
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Brain Trust Accelerator Fund, VC Fund

Brain Trust Accelerator Fund

VC Fund

Burlingame, United States

Brain Trust Accelerator Fund is a VC fund in Burlingame focused on Health Care and Pharmaceutical. The Brain Trust Accelerator Fund focuses on early stage investments that address the diagnosis and treatment of brain related diseases.

Total investments:
6
Last investment:
Lead investor:
17%

Last updated:

Industries Brain Trust Accelerator Fund invests in

Health CarePharmaceuticalTherapeuticsAppsBeauty

Stages Brain Trust Accelerator Fund invests in

Series BSeedSeries AFunding Round

Countries Brain Trust Accelerator Fund invests in

United States

Investment Focus

Industry

  • Health Care 3 (50%)
  • Pharmaceutical 3 (50%)
  • Therapeutics 2 (33%)
  • Apps 1 (17%)
  • Beauty 1 (17%)
See all 11 industries →

Stage

  • Series B 3 (50%)
  • Seed 1 (17%)
  • Series A 1 (17%)
  • Funding Round 1 (17%)

Investments

CompanyDescriptionRoundLinks
Neuro Therapia Neuro Therapia
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. $12.3M / Series B / Aug 06, 2024
MyAvana MyAvana
MyAvana, formerly known as Madame You, provides hair care recommendation system, combining artificial intelligence and hair care experts to support and guide women with their hair care. It offers a hair analysis service to recommend the best hair products and styling techniques for your unique hair type and texture. Jan 11, 2024
MyAvana MyAvana
MyAvana, formerly known as Madame You, provides hair care recommendation system, combining artificial intelligence and hair care experts to support and guide women with their hair care. It offers a hair analysis service to recommend the best hair products and styling techniques for your unique hair type and texture. Seed / Jan 10, 2024
Chase Therapeutics Chase Therapeutics
Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease. $20M / Series B / Oct 20, 2021
Neuro Therapia Neuro Therapia
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. $8.8M / Series A / Sep 22, 2020
Satoris Satoris
Satoris develops tests for neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. They're committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patientcare becomes even more effective. $5.2M / Series B / Mar 25, 2008

Co-Investors

Cleveland Clinic Cleveland Clinic 3 deals together Alzheimer's Drug Discovery Foundation Alzheimer's Drug Discovery Foundation 2 deals together Dolby Family Ventures Dolby Family Ventures 2 deals together
Prisma Ventures Prisma Ventures 2 deals together
China Link Capital 1 deal together
CRUINT CRUINT 1 deal together

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Recruiting
Life Science
Food and Beverage
Publishing
Web3
Mobile Apps
Medical
Wine and Spirits
Theatre
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Franchise
Financial Services
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Enterprise
Biotech
Transportation
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Singapore
Brazil
Oman
LATAM
Poland
Puerto Rico
Cameroon
Guernsey
China
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Ireland
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Europe
Qatar
Angola
Cyprus
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Grenada
Hungary
Lithuania
Israel
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Brain Trust Accelerator Fund invest in?

Brain Trust Accelerator Fund invests primarily in Health Care, Pharmaceutical and Therapeutics startups, most often at Series B and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Brain Trust Accelerator Fund last invest?

The most recent investment recorded for Brain Trust Accelerator Fund closed in Aug 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Brain Trust Accelerator Fund Brain Trust Accelerator Fund Find emails